Groowe Groowe / Newsroom / ACIU
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

ACIU News

AC Immune SA

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

globenewswire.com
ACIU

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

globenewswire.com
ACIU

AC Immune First Half 2026 Financial and Corporate Update

globenewswire.com
ACIU

Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight

globenewswire.com
AZN LLY NVO PFE AMGN BMY JNJ REGN VKTX ZETA CRSP IONS AXSM MRK GSK SNY IMUX BMEA ALKS ALT AARD NOV CARM CRIS LPCN GILD REG SPRO ABSI ALZN ANVS BV ARCL ACIU

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026

globenewswire.com
ACIU

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease

globenewswire.com
ACIU

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

globenewswire.com
ACIU

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

globenewswire.com
ACIU

Davos Alzheimer’s Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer’s Policy, Research and Care

globenewswire.com
ACIU

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

globenewswire.com
ACIU